Merck Manual

Please confirm that you are a health care professional

honeypot link

Overview of Pancreatic Endocrine Tumors


Minhhuyen Nguyen

, MD, Fox Chase Cancer Center, Temple University

Last full review/revision Mar 2021| Content last modified Mar 2021
Click here for Patient Education
Topic Resources

Pancreatic endocrine tumors arise from islet and gastrin-producing cells and often produce many hormones. Although these tumors develop most often in the pancreas, they may appear in other organs, particularly the duodenum, jejunum, and lung.

These tumors have two general manifestations:

  • Functioning

  • Nonfunctioning

Nonfunctioning tumors may cause obstructive symptoms of the biliary tract or duodenum, bleeding into the gastrointestinal tract, or abdominal masses.

Functioning tumors hypersecrete a particular hormone, causing various syndromes (see Table: Pancreatic Endocrine Tumors). These clinical syndromes can also occur in multiple endocrine neoplasia, in which tumors or hyperplasia affects two or more endocrine glands, usually the parathyroid, pituitary, thyroid, or adrenals.


Pancreatic Endocrine Tumors



Tumor Location

Symptoms and Signs





Pancreas (60%)

Duodenum (30%)

Other (10%)

Abdominal pain, peptic ulcer, diarrhea



Glucose intolerance, rash, weight loss, anemia


Growth hormone releasing factor

Lung (54%)

Pancreas (30%)

Jejunum (7%)

Other (13%)



Fasting hypoglycemia



Pancreas (56%)

Duodenum/jejunum (44%)

Glucose intolerance, diarrhea, gallstones

Vasoactive intestinal peptidase

Pancreas (90%)

Other (10%)

Severe watery diarrhea, hypokalemia, flushing

Treatment of Pancreatic Endocrine Tumors

  • Surgical resection

Treatment for functioning and nonfunctioning tumors is surgical resection. If metastases preclude curative surgery, various antihormone treatments (eg, octreotide, lanreotide) may be tried for functioning tumors. Because of tumor rarity, chemotherapy trials have not yet identified definitive treatment. Streptozotocin has selective activity against pancreatic islet cells and is commonly used, either alone or in combination with 5-fluorouracil or doxorubicin. Some centers use chlorozotocin and interferon.

Newer chemotherapeutic regimens that include temozolomide, either alone or in combination with other agents (eg, thalidomide, bevacizumab, everolimus, capecitabine), have shown good results in small clinical trials and are under active investigation in large prospective clinical trials.

Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID